Key Points
- Pulse Biosciences COO Liane Rae Teplitsky bought $49,971 worth of stock at an average price of $48.80, increasing her direct ownership by 49.47% to 3,094 shares. She also made three other purchases totaling nearly $150,000 in late August and early September.
- PLSE shares opened at $52.68, near their 52-week high of $54.39, with a market capitalization of approximately $3.65 billion. However, the company reported a larger-than-expected quarterly loss of $0.36 per share and revenue below analyst estimates.
- Analyst sentiment is broadly positive, with four Buy ratings and one Sell rating, producing a consensus “Moderate Buy” rating and a $45.25 target price. Institutional investors own nearly 77% of the stock, including new positions from BlackRock and Bank of America.
Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) COO Liane Rae Teplitsky purchased 1,024 shares of the company's stock in a transaction on Monday, August 31st. The stock was bought at an average price of $48.80 per share, for a total transaction of $49,971.20. Following the completion of the purchase, the chief operating officer directly owned 3,094 shares of the company's stock, valued at $150,987.20. The trade was a 49.47% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Liane Rae Teplitsky also recently made the following trade(s):
- On Tuesday, September 1st, Liane Rae Teplitsky bought 1,001 shares of Pulse Biosciences stock. The stock was bought at an average price of $49.95 per share, with a total value of $49,999.95.
- On Friday, August 28th, Liane Rae Teplitsky bought 1,034 shares of Pulse Biosciences stock. The stock was bought at an average cost of $48.35 per share, for a total transaction of $49,993.90.
- On Wednesday, August 26th, Liane Rae Teplitsky purchased 1,036 shares of Pulse Biosciences stock. The shares were bought at an average price of $48.23 per share, for a total transaction of $49,966.28.
Pulse Biosciences Price Performance
Shares of PLSE opened at $52.68 on Thursday. Pulse Biosciences, Inc has a 1-year low of $12.56 and a 1-year high of $54.39. The stock has a market cap of $3.65 billion, a PE ratio of -44.64 and a beta of 1.63. The firm has a fifty day moving average price of $36.93 and a 200 day moving average price of $27.60.
Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The company had revenue of $0.43 million during the quarter, compared to analyst estimates of $0.53 million. Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. As a group, equities analysts expect that Pulse Biosciences, Inc will post -1.29 EPS for the current fiscal year.
Analyst Ratings Changes
A number of analysts recently issued reports on the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Oppenheimer reaffirmed an "outperform" rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Canaccord Genuity Group boosted their price objective on Pulse Biosciences from $32.00 to $43.00 and gave the company a "buy" rating in a research note on Monday, August 10th. Needham & Company LLC assumed coverage on Pulse Biosciences in a report on Monday, August 17th. They issued a "buy" rating and a $58.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Pulse Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday, August 29th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Pulse Biosciences currently has an average rating of "Moderate Buy" and a consensus target price of $45.25.
Get Our Latest Stock Report on Pulse Biosciences
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in shares of Pulse Biosciences in the second quarter valued at about $40,672,000. Bank of America Corp DE purchased a new position in shares of Pulse Biosciences during the second quarter worth about $40,115,000. California State Teachers Retirement System grew its holdings in shares of Pulse Biosciences by 2,600.0% during the second quarter. California State Teachers Retirement System now owns 567,883 shares of the company's stock worth $15,747,000 after buying an additional 546,850 shares during the last quarter. Portolan Capital Management LLC acquired a new position in Pulse Biosciences in the 3rd quarter valued at about $1,809,000. Finally, Brooklyn Investment Group increased its position in Pulse Biosciences by 330.7% in the 4th quarter. Brooklyn Investment Group now owns 130,340 shares of the company's stock valued at $1,844,000 after acquiring an additional 100,081 shares during the period. 76.95% of the stock is currently owned by institutional investors and hedge funds.
Pulse Biosciences Company Profile
(
Get Free Report)
Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.
The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
